UA138725U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the gene polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, C-terminal propeptide of collagen type I (CISR), C-reactive protein and C-reactive protein. -TT, 786-SS and endothelin levels> 10 ng / ml, SISR <102 ng / ml, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

Useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

C677T), nitric oxide synthase (EMO5 T786C), content of endothelin, C-terminal propeptide of collagen

Type I (SISR), C-reactive protein (SRP), homocysteine. With homozygous carrier 677-177, 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, SISR, SRP, homocysteine is determined by the immunoenzymatic method. With homozygous carriers of 677-HT, 786-SS, endothelin levels of 210 ng/ml, SISR "102 ng/ml, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient G., 60 years old, was hospitalized for pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of endothelin, SISR, SRP, and homocysteine was determined by immunoenzymatic method. Established homozygous carrier 67 7-

TT and 786-SS, endothelin levels - 25 ng/ml, SISR - 85 ng/ml, SRP - 18 mg/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, X-ray photography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (2ЕМО5 1786С), the content of endothelin, the C-terminal propeptide of collagen is determined | type (SISR), C-reactive protein (SRP), homocysteine and homozygous carriers of 677-TT, 786-SS and levels of endothelin 210 ng/ml, SISR "102 ng/ml, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.